Status:

COMPLETED

Controlled Acute Hypoxia Study - Abbreviated Sensor Line

Lead Sponsor:

Medtronic - MITG

Conditions:

Healthy

Hypoxia

Eligibility:

All Genders

18-50 years

Brief Summary

The primary objective of the study is to validate the proposed claims for the OxiCable device, for pulse rate and saturation accuracy in a diverse subject population over a specified saturation range.

Detailed Description

The general procedure of invasive controlled hypoxia clinical studies is to directly compare test pulse oximeter measurements to saturation measurements made by a multi-wavelength CO-oximeter taken fr...

Eligibility Criteria

Inclusion

  • Male or female of any race
  • 18-50 years old, inclusive
  • Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia)
  • Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening)
  • Meets specific demographic requirements for the monitoring device under study
  • Willing and able to provide written informed consent
  • Able to participate for the duration of the evaluation

Exclusion

  • Under 18 years or over 50 years of age
  • Pregnant and/or lactating women
  • Hypertension: on three consecutive readings, systolic pressure greater than 145 mm Hg or diastolic pressure greater than 90 mm Hg
  • Premature ventricular contractions (PVCs) that are symptomatic or occur at a rate of more than four per minute
  • History of seizures (except childhood febrile seizures) or epilepsy
  • History of unexplained syncope
  • Daily or more frequent use of anxiolytic drugs (benzodiazepines) for treatment of anxiety disorder
  • Recent history of frequent migraine headaches: average of two or more per month over the last year
  • Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test site needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • History of acute altitude sickness at or below moderate elevation (up to 5,000-10,000 feet) defined as three or more of the following symptoms: moderate to severe headache, general malaise, dizziness/lightheadedness, nausea/vomiting, fatigue/weakness, shortness of breath, nosebleed, persistent rapid pulse, or peripheral edema
  • History of significant respiratory disease such as severe asthma or emphysema
  • Sickle cell disease or trait
  • Clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or study physician as designated.
  • History of stroke, transient ischemic attack or carotid artery disease
  • History of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy
  • History of chronic renal impairment
  • Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • Unwillingness or inability to remove colored nail polish from test digit(s)
  • Unwillingness or inability to give informed consent
  • Prior or known allergies to: lidocaine (or similar pharmacological agents, e.g., Novocain) or heparin
  • Recent arterial cannulation (i.e., less than 30 days prior to study date)
  • Six or more arterial cannulations of each (right \& left) radial artery
  • History of clinically significant complications from previous arterial cannulation
  • Current use of blood thinners: prescription or daily aspirin use

Key Trial Info

Start Date :

August 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2014

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT02216344

Start Date

August 1 2014

End Date

September 1 2014

Last Update

September 30 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boulder Clinical Laboratory

Boulder, Colorado, United States, 80301